Zetia Cost in Texas 2026: Ezetimibe Prices, Insurance, and Savings

Ezetimibe is the generic name; Zetia is the original brand name from Merck. It is also sold in fixed-dose combination with simvastatin (Vytorin) and with atorvastatin (Liptruzet). Ezetimibe is an oral, non-statin, prescription-only cholesterol-lowering drug, not a compounded peptide or supplement, and it is not a controlled substance.

Ezetimibe blocks the NPC1L1 transporter in the small intestine, reducing cholesterol absorption. The FDA approved it for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia, either alone or added to a statin. Generic ezetimibe 10 mg has been approved and marketed in the United States since patent exclusivity on brand Zetia ended in 2017, and multiple manufacturers currently supply the generic market; current listings can be confirmed in the FDA's Orange Book search tool. Texas Medicaid, through the Texas Vendor Drug Program, restricts routine coverage of ezetimibe to certain diagnoses and requires prior authorization outside that criteria, while generic cash-pay pricing programs such as Cost Plus Drugs make the drug accessible to most Texas residents regardless of insurance status.

Why brand-name Zetia and generic ezetimibe pricing diverge

Brand Zetia has historically carried a list price far above the cost of the generic, and that gap is one of the largest, proportionally, among common cardiovascular drugs. This is expected once a molecule loses exclusivity and multiple manufacturers compete on price. It does not reflect a difference in the active drug; FDA-approved generics must meet bioequivalence standards under federal regulation before approval.

What is stable: patent exclusivity on Zetia ended in 2017, and FDA-approved generic ezetimibe 10 mg tablets have been commercially available since then. The FDA's Orange Book lists currently approved ezetimibe products and can be checked directly.

What is volatile and needs verification at the time you fill a prescription: the brand list price, the generic cash price at any specific Texas pharmacy chain, and the price on a discount card or Cost Plus Drugs. Retail cash prices change by pharmacy, by month, and by whether a coupon or discount card is applied. Any specific dollar figure quoted for "2026" should be treated as illustrative until confirmed with the pharmacy or the pricing site directly, not as a guaranteed rate. Cost Plus Drugs publishes a current generic ezetimibe price on its own site (costplusdrugs.com), which is the most reliable way to check today's number rather than relying on a fixed figure printed here.

Why some patients still pay brand pricing: an older prescription written specifically as "Zetia" with a dispense-as-written instruction, or a formulary that has not updated, can result in brand dispensing. Under Texas Health and Safety Code Section 562.014, a pharmacist may substitute a generically equivalent drug unless the prescriber has specified dispense as written. Confirming that a prescription is written for "ezetimibe 10 mg" rather than "Zetia," without a DAW restriction, is the single most reliable lever a patient has over cost.

Does Texas Medicaid cover ezetimibe?

Texas Medicaid's Vendor Drug Program maintains a preferred drug list, and ezetimibe's coverage status depends on diagnosis and current formulary rules, which are published and updated by the Texas Health and Human Services Commission. Drugs not on the preferred list generally require prior authorization, and a patient without the qualifying diagnosis criteria should expect a prior authorization step or a denial without one.

For a Texas Medicaid patient facing a denial or prior authorization delay, three realistic paths exist:

1. A prior authorization request documenting statin intolerance or elevated cardiovascular risk, referencing current national lipid-management guidance.
2. Cash-pay generic ezetimibe, which for many patients costs less out of pocket than the copay or administrative burden of appealing a denial.
3. Manufacturer or independent patient assistance programs (see below), which are not tied to Medicaid enrollment.

Because Medicaid formulary rules change on a regular cycle, the current preferred drug list and prior authorization criteria should be checked directly through the Texas Vendor Drug Program rather than assumed from a prior year's rule.

Private insurance formulary tiers in Texas

Generic drugs, including ezetimibe, are typically placed on a lower formulary tier than the corresponding brand product, and Texas does not have a state law dictating a specific tier for this drug. Actual tier placement and copay amount vary by plan, by employer, and by benefit year, including among the major carriers operating in Texas. There is no single correct copay figure that applies across all Texas plans.

A practical and low-risk habit for any Texas patient: ask the pharmacist to run the insurance claim and a discount-card price (GoodRx, SingleCare, or similar) side by side before deciding which to use. It is common for generic drugs, including ezetimibe, for the cash discount price to be lower than an insurance copay, particularly on a high-deductible plan or before the deductible is met. There is no requirement to use insurance for every prescription.

Manufacturer savings cards and patient assistance

Merck is reported to offer a savings program for brand Zetia and a separate patient assistance program for eligible uninsured or underinsured patients, administered through Merck's own enrollment channel. Manufacturer savings cards for brand-name drugs generally cannot be used with federally funded insurance, including Medicaid and Medicare Part D, under federal anti-kickback rules; patients on those programs should not expect the card to apply. Income eligibility thresholds for patient assistance programs are set by the manufacturer and change; current criteria should be confirmed directly with the manufacturer rather than assumed from a prior year.

Because multiple manufacturers produce generic ezetimibe, there is generally no single-manufacturer savings card for the generic version. Independent discount programs, including NeedyMeds and standard pharmacy discount cards, list generic ezetimibe among covered medications without an income requirement, though exact prices through any specific card should be checked at the time of use.

Is compounded ezetimibe legal in Texas?

A Texas-licensed 503A compounding pharmacy may legally compound ezetimibe for an individual patient under a valid, patient-specific prescription. This is governed by Section 503A of the Federal Food, Drug, and Cosmetic Act and by Texas State Board of Pharmacy compounding rules, which apply USP Chapter 795 standards to non-sterile preparations such as an oral ezetimibe capsule or suspension.

Two points matter for a patient considering this route. First, compounded drugs are not FDA-approved products and have not gone through the bioequivalence testing that generic ezetimibe must pass; a compounded version is not guaranteed to behave identically to the approved generic. Second, federal guidance restricts bulk 503B outsourcing-facility compounding of a drug when an FDA-approved, commercially available version exists and the drug is not on an FDA drug shortage list. As of this writing, ezetimibe is commercially available as an approved generic and compounding for individual patients under 503A is legally permitted, while large-scale 503B compounding for general stock is not the expected legal route for this drug. Whether ezetimibe is on the FDA shortage list can change and should be checked directly against the FDA's own compounding and shortage resources before relying on this distinction for a specific decision.

Verification checklist: what is stable versus what needs a fresh check

This checklist separates facts that come from federal law, regulation, or established clinical evidence (unlikely to change soon) from facts that depend on a specific insurer, pharmacy, or date (likely to change and should be reconfirmed before a patient relies on them).

Stable, federal or clinical facts (unlikely to change without a formal regulatory or guideline update):

• Ezetimibe's FDA-approved indications (primary hypercholesterolemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia) and its mechanism as an NPC1L1 inhibitor.
• Patent exclusivity for brand Zetia ended in 2017, opening the market to FDA-approved generics.
• Ezetimibe is not a controlled substance and does not require special DEA prescriptive authority.
• Texas law (Health and Safety Code 562.014) allows pharmacist generic substitution unless a prescriber specifies dispense as written.
• 503A compounding of ezetimibe for an individual patient is legally permitted under federal and Texas Board of Pharmacy rules when a valid prescription exists.
• Texas telehealth prescribing rules generally permit prescribing of non-controlled drugs like ezetimibe after a valid provider-patient relationship is established.

Date-sensitive facts that require a fresh check before you rely on them:

• The current brand Zetia list price and any specific generic cash price at a named Texas pharmacy or discount site.
• Whether ezetimibe currently appears on the Texas Medicaid Vendor Drug Program preferred drug list, and what diagnosis or prior authorization criteria currently apply.
• Which formulary tier your specific private insurance plan places generic versus brand ezetimibe on this benefit year.
• Whether ezetimibe currently appears on the FDA drug shortage list, which affects the legality of larger-scale 503B compounding.
• Current income thresholds and enrollment terms for the Merck patient assistance program.
• Whether a specific 503A compounding pharmacy currently holds an active, unrestricted Texas State Board of Pharmacy license (checked through the board's license search).

What the trial evidence for ezetimibe actually shows

Ezetimibe's cardiovascular outcome evidence rests primarily on IMPROVE-IT, a large randomized trial in patients with recent acute coronary syndrome that compared a statin plus ezetimibe against the statin alone and was published in the New England Journal of Medicine in 2015. The trial reported a modest but statistically significant reduction in cardiovascular events with the combination compared with statin monotherapy. Because this draft could not independently re-verify the exact effect-size figures and confidence intervals against the primary publication, editors should confirm the precise numbers directly from the NEJM article or a current systematic review before publishing any specific percentage or hazard ratio as fact.

National lipid-management guidelines from cardiology societies position ezetimibe as a reasonable first non-statin add-on for patients who remain above LDL-C treatment targets on maximally tolerated statin therapy, and as an option for statin-intolerant patients, generally ahead of costlier PCSK9 inhibitor injectables such as evolocumab or alirocumab. That sequencing reflects both the trial evidence and the large cost difference between an oral generic tablet and an injectable biologic, though exact current list prices for PCSK9 inhibitors should be checked separately, as biologic pricing changes frequently.

Dosing, safety, and monitoring

The FDA-approved dose of ezetimibe is one 10 mg tablet daily, with or without food, without a titration schedule. It is not recommended in patients with moderate to severe hepatic impairment. Reported drug interactions include reduced ezetimibe absorption when taken with certain bile acid sequestrants (cholestyramine, colesevelam), increased ezetimibe exposure with cyclosporine, and a labeled caution about combined use with fibrates. Standard practice includes a follow-up fasting lipid panel roughly one to three months after starting therapy to confirm response. This article does not provide individualized dosing advice; a prescriber should tailor the regimen, monitoring interval, and any statin combination to the individual patient's history, liver function, and other medications.

Ezetimibe should not be started or stopped based on cost pressure alone without talking to the prescribing clinician, since abrupt changes in lipid-lowering therapy in a patient with established cardiovascular disease carry real, though usually gradual, risk. A patient experiencing new muscle pain, jaundice, dark urine, or signs of an allergic reaction while on ezetimibe, especially in combination with a statin, should contact their prescriber promptly and seek urgent care for severe or rapidly worsening symptoms.

Telehealth prescribing in Texas

Texas law permits a licensed physician or an APRN with prescriptive authority to prescribe non-controlled drugs, including ezetimibe, following a valid telehealth visit that establishes a provider-patient relationship under state telehealth prescribing rules. Because ezetimibe is not a controlled substance, no additional DEA registration step applies. A typical telehealth visit for lipid management involves review of a recent lipid panel and cardiovascular risk assessment before a prescribing decision; exactly how quickly a prescription reaches a pharmacy depends on the platform and pharmacy, and no fixed turnaround time should be presented as guaranteed.

Evidence boundary: what is established, what is not

Established: Ezetimibe is FDA-approved for the indications listed above; generic versions have been available since 2017 and must meet bioequivalence standards; Texas law allows generic substitution absent a dispense-as-written order; 503A compounding of ezetimibe for individual patients is legally permitted in Texas; telehealth prescribing of ezetimibe is legal in Texas under Texas Medical Board rules; a large randomized trial (IMPROVE-IT) found a cardiovascular benefit from adding ezetimibe to statin therapy in a post-ACS population.

Plausible but requiring verification before quoting as fact: the exact size of that cardiovascular benefit (specific percentage or hazard ratio), any specific dollar price for brand or generic ezetimibe in Texas today, current Texas Medicaid coverage criteria, and current FDA drug-shortage status for ezetimibe.

Not established from the material available for this page: that any specific Texas retail chain reliably charges a fixed price, that any specific insurer's copay for ezetimibe is a set dollar figure, or that compounded ezetimibe is cheaper than the generic in a typical case. Pricing claims of this kind vary too much by plan, pharmacy, and date to state as a stable fact and should be checked directly by the reader.

This article is a draft for editorial and qualified medical review. It has not yet received clinical or pharmacy-benefit sign-off. Specific dollar prices, insurer tier placements, and Medicaid formulary status should be independently verified before publication, and re-verified periodically after, since these details change on a schedule outside the control of this article.